logo
ProjectGrant Award

Targeting Cell Death Pathways in Malignant Mesothelioma

Grant award · Australia · Last reported Dec 2018

Source: GrantConnect

Malignant mesothelioma (MM) is an aggressive and incurable cancer with median patient survival of 12 months. By screening a panel of MM cell lines against a new class of drugs that directly target the natural cell death mechanisms in tumour cells, we identified two specific 'survival factors' in MM. Co-targeting of these molecules leads to potent MM cell killing. The proposed research will expand

Status
Prospective
Sector
Education, Hospital, Government
Location
Australia
Updated
19 Nov 2026
Source
GrantConnect

ConstructChat

Ask ConstructChat about Targeting Cell Death Pathways in Malignant Mesothelioma

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

5 Q
The project “Targeting Cell Death Pathways in Malignant Mesothelioma” is an infrastructure initiative in the Education sector, located in Australia. Taiyo aggregates data on it from GrantConnect.

Participants

Sponsoring Agency

Status

Original status

grant award

Taiyo status

Prospective

Taiyo last update

2026-11-19

Contact

Not available for this record.

Description

Description

Malignant mesothelioma (MM) is an aggressive and incurable cancer with median patient survival of 12 months. By screening a panel of MM cell lines against a new class of drugs that directly target the natural cell death mechanisms in tumour cells, we identified two specific 'survival factors' in MM. Co-targeting of these molecules leads to potent MM cell killing. The proposed research will expand these studies into animal model of MM and potentially provide new treatment options for MM patients.

Original sector

Medical Research

Budget

Location

Country

Australia

Source

Source

GrantConnect

URL

More Details

Record type

Project

Sector

Education, Hospital, Government

Article published date

2024-12-16

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project